Transgene (TNG) Hisse Özeti
Bir biyoteknoloji şirketi olan Transgene SA, Fransa'da kanser tedavisi için terapötik aşılar ve onkolitik virüsler tasarlamakta ve geliştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
TNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Transgene SA Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €0.83 |
| 52 Haftanın En Yüksek Seviyesi | €1.50 |
| 52 Haftanın En Düşük Seviyesi | €0.58 |
| Beta | 0.73 |
| 1 Aylık Değişim | 10.08% |
| 3 Aylık Değişim | 0.97% |
| 1 Yıllık Değişim | 36.07% |
| 3 Yıllık Değişim | -52.89% |
| 5 Yıllık Değişim | -72.65% |
| Halka arzdan bu yana değişim | -98.16% |
Son Haberler & Güncellemeler
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).Recent updates
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...Hissedar Getirileri
| TNG | FR Biotechs | FR Pazar | |
|---|---|---|---|
| 7D | -1.1% | 3.4% | 2.0% |
| 1Y | 36.1% | 344.2% | 1.3% |
Getiri vs. Endüstri: TNG geçen yıl % 344.2 oranında getiri sağlayan French Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: TNG geçen yıl % 1.3 oranında getiri sağlayan French Piyasasını aştı.
Fiyat Oynaklığı
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: TNG son 3 ayda French piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: TNG 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1979 | 145 | Alessandro Riva | www.transgene.fr |
Bir biyoteknoloji şirketi olan Transgene SA, Fransa'da kanser tedavisi için terapötik aşılar ve onkolitik virüsler tasarlamakta ve geliştirmektedir. Yumurtalık kanseri ve baş ve boyun kanserlerinin tedavisi için Faz II klinik çalışmasında olan terapötik bir aşı olan TG4050'nin; insan papilloma virüsü (HPV 16) pozitif kanserlerin tedavisi için Faz II klinik çalışmasında olan terapötik bir aşı olan TG4001'in geliştirilmesinde yer almaktadır; Gastrointestinal adenokarsinom dahil olmak üzere solid tümörlerin tedavisi için Faz I/IIa klinik çalışmasında olan bir onkolitik virüs olan TG6002; ve solid tümörlerin tedavisi için Faz I/II klinik çalışmasında olan bir onkolitik virüs olan BT-001. Şirket ayrıca, Faz 1 klinik çalışmasında olan küçük hücreli dışı akciğer kanseri tedavisi için TG6050'yi ve solid tümörlerin tedavisi için onkolitik bir virüs olan Pexa-Vec'i geliştirmektedir.
Transgene SA Temel Bilgiler Özeti
| TNG temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €227.32m |
| Kazançlar(TTM) | -€37.52m |
| Gelir(TTM) | €7.21m |
TNG aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| TNG gelir tablosu (TTM) | |
|---|---|
| Gelir | €7.21m |
| Gelir Maliyeti | €33.90m |
| Brüt Kâr | -€26.69m |
| Diğer Giderler | €10.84m |
| Kazançlar | -€37.52m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
Sep 24, 2026
| Hisse başına kazanç (EPS) | -0.14 |
| Brüt Marj | -370.12% |
| Net Kâr Marjı | -520.44% |
| Borç/Özkaynak Oranı | 1.7% |
TNG uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 04:39 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Transgene SA 5 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |